{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(9)"],"submitter":["Dello Russo A"],"pubmed_abstract":["<h4>Background</h4>There is no evidence evaluating efficiency, effectiveness, and safety outcomes in older patients in the context of pulsed-field ablation technology for the ablation of atrial fibrillation. We aimed to compare safety, efficacy, and acute and long-term outcomes of pulsed-field ablation in older patients (≥75 years) with younger ones.<h4>Methods</h4>We enrolled consecutive patients who had undergone atrial fibrillation ablation with the pulsed-field ablation FARAPULSE system (Boston Scientific) at 15 centers. Patients were stratified by age (<65, 65-74, and ≥75 years) and efficacy and safety profiles of these groups were compared.<h4>Results</h4>A total of 1082 patients were included: 108 (10%) were ≥75 years old, 374 (34.6%) were 65-74 years old and 600 (55.4%) were <65 ye"],"journal":["Journal of the American Heart Association"],"pagination":["e037959"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12184239"],"repository":["biostudies-literature"],"pubmed_title":["Does Age Impact Safety and Efficacy During Pulse-Field Ablation for Atrial Fibrillation?"],"pmcid":["PMC12184239"],"pubmed_authors":["Solimene F","Valeri Y","Russo M","De Simone A","Schillaci V","Viola G","Colella J","Compagnucci P","Rossi P","Zucchelli G","Tondo C","Rossillo A","Bianchi S","Casella M","Bertini M","Di Vilio A","Dello Russo A","Rordorf R","Volpicelli M","Malacrida M","Iacopino S","Schiavone M","Tundo F","Zingarini G","Themistoclakis S","Bianchini L","Maggio R"],"additional_accession":[]},"is_claimable":false,"name":"Does Age Impact Safety and Efficacy During Pulse-Field Ablation for Atrial Fibrillation?","description":"<h4>Background</h4>There is no evidence evaluating efficiency, effectiveness, and safety outcomes in older patients in the context of pulsed-field ablation technology for the ablation of atrial fibrillation. We aimed to compare safety, efficacy, and acute and long-term outcomes of pulsed-field ablation in older patients (≥75 years) with younger ones.<h4>Methods</h4>We enrolled consecutive patients who had undergone atrial fibrillation ablation with the pulsed-field ablation FARAPULSE system (Boston Scientific) at 15 centers. Patients were stratified by age (<65, 65-74, and ≥75 years) and efficacy and safety profiles of these groups were compared.<h4>Results</h4>A total of 1082 patients were included: 108 (10%) were ≥75 years old, 374 (34.6%) were 65-74 years old and 600 (55.4%) were <65 ye","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-03T06:56:21.181Z","creation":"2026-04-25T03:22:05.668Z"},"accession":"S-EPMC12184239","cross_references":{"pubmed":["40265595"],"doi":["10.1161/JAHA.124.037959"]}}